On Tuesday, Cheniere Energy, Inc. (NYSEMKT:LNG)’s shares inclined 1.36% to $69.42.
Cheniere Energy, Inc. (LNG) project developments that, if accomplished, are projected to add up to about 19 million tonnes per annum (“mtpa”) of incremental LNG production capacity and would bring Cheniere’s aggregate nominal LNG production capacity to about 60 mtpa by 2025.
Cheniere is developing about 9 mtpa of incremental LNG production capacity through the addition of two liquefaction trains adjacent to the existing site of the Corpus Christi liquefaction project (the “CCL Project”). Predictable nominal LNG production capacity of each of these liquefaction trains is about 4.5 mtpa, which would enhance the predictable aggregate nominal LNG production capacity at the CCL Project to about 22.5 mtpa. Cheniere initiated the regulatory process in June 2015 by filing the National Environmental Policy Act pre-filing request with the FERC and the FTA and non-FTA approval requests with the DOE. Regulatory approvals would be predictable in 2017.
Cheniere Energy, Inc., an energy company, engages in the liquefied natural gas (LNG) related business. It operates through two segments, LNG Terminal Business, and LNG and Natural Gas Marketing Business. The company owns and operates Sabine Pass LNG terminal in western Cameron Parish, Louisiana; and Corpus Christi LNG terminal near Corpus Christi, Texas.
Real Goods Solar, Inc. - Class A (NASDAQ:RGSE)’s shares dropped -16.17% to $2.23.
Real Goods Solar, Inc. (the “Company”), reached a Securities Purchase Agreement (the “Purchase Agreement”) with several institutional and accredited investors (the “Institutional Investors”). Pursuant to the terms of the Purchase Agreement, the Company will sell to the Institutional Investors an aggregate of $4.2 million of units (each, a “Unit”) of the Company’s Class A common stock, par value $0.0001 per share, (the “Common Stock”), and Series F Warrants (the “Warrants”). On the same day, the Company agreed to sell $800,000 of Units to additional investors. The purchase price for each Unit is $3.65. Each Unit comprises of: (i) one share of Common Stock, and
(ii) a Warrant to purchase 30% of one share of Common Stock.
In the event that an investor, together with certain “attribution parties,” would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding right away after the closing of the offering as a result of its purchase of Units, the Company will issue to such investor shares of Common Stock in an amount up to such 9.99% cap. The balance of the shares of Common Stock such investor would have received at closing but for the 9.99% cap will be issued and placed into escrow with the Company’s transfer agent following the terms of an escrow agreement and will be delivered to such investor from time to time, offered that at any such time any such investor, together with certain “attribution parties,” would not beneficially own, after such delivery, more than 9.99% of the issued and outstanding shares of Common Stock.
There will be a one-time “reset” adjustment of the number of shares of Common Stock issuable as part of the Units. At the time of closing the Company will deliver into escrow, with the Company’s transfer agent, an estimated number of “reset shares.” On July 10, 2015, the escrow agent will deliver to the investors in the offering additional shares equal to the number of shares a purchaser would have received at closing had the per Unit price at closing been equal to a “reset price” calculated on July 9, 2015, minus the total number of shares purchased and delivered as part of the Units at closing (without regard to whether such shares are delivered to the purchases or held in escrow following the 9.99% cap described above). The reset price will be equal to 85% of the arithmetic average of the three lowest volume weighted average prices of the Common Stock during the period commencing on the date of the Purchase Agreement and ending on July 9, 2015.
Real Goods Solar, Inc. operates as a residential and commercial solar energy engineering, procurement, and construction company in the United States. It operates in three segments: Residential, Sunetric, and Other. The company offers solar energy services, including design, procurement, permitting, build-out, grid connection, financing referrals, and warranty and customer satisfaction. It installs residential solar energy systems up to 15 kilowatts (kW) output; and small commercial solar energy systems up to 200 kW output for various industries, such as retail, manufacturing, service, and municipal services.
At the end of Tuesday’s trade, NCR Corporation (NYSE:NCR)‘s shares dipped -0.07% to $30.10.
NCR Corporation (NCR) declared that Tesco Stores Ltd. – a partner of U.K.-based Tesco plc – has selected its self-checkout technology for the Malaysian stores. The grocery and general merchandise retailer selected The Tesco store at IOI City Mall in Putrajaya for the pilot deployment. The technology will be installed later at Tesco KSL City in Johor.
The full touch screen NCR self-checkout solution has a user-friendly interface that will guide shoppers through the checkout process. The animated demonstrations on the screen make the technology user-friendly and faster thereby enhancing customers overall shopping experience.
The customers will save a lot of time as this technology will enable them to scan, bag and pay for goods themselves. Per the deal, NCR will provide consulting, training and services to ensure smooth deployment of the technology at Tesco Stores in Malaysia.
RXi Pharmaceuticals Corp (NASDAQ:RXII), ended its Tuesday’s trading session with -4.72% loss, and closed at $0.490.
RXi Pharmaceuticals Corp (RXII) declared that it received two Notices of Allowance from the United States Patent and Trademark Office (USPTO). One is on RXi’s novel, self-delivering RNAi platform (sd‑rxRNA®). The patent, titled “Reduced Size Self-Delivering RNAi Compounds,” covers both the composition and methods of use of RXi’s self-delivering platform. The patent, once issued, will be planned to expire in 2031.
In addition, RXi declared that it has also received a Notice of Allowance from the USPTO covering the composition and methods of use for rxRNAori® compounds targeting Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). These compounds may be beneficial for the treatment of inflammatory diseases and/or metabolic diseases. RXi’s rxRNAori platform are highly potent RNAi compounds which require delivery vehicles to be taken up by cells and tissues of interest. The patent, once issued, will be planned to expire in 2029.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs comprise RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, in addition to for the administration of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
